Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Last trade$3.02
Day change$0.00 (0.00%)
Day range$2.92 – $3.10
Volume97,414
Market cap$526M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$525.9M
Price / earnings
—
Price / book
1.92×
Price / sales
—
EV / sales
—
EV / EBITDA
-14.17×
Profitability
Earnings per share
-$0.17
Return on assets
-10.62%
Return on equity
-10.73%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
128.41×
Quick ratio
128.41×
Cash ratio
123.49×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.84M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ENTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$42K
$82K
Cost of revenue
$0
$0
$0
$0
$0
$0
$42K
$82K
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.34M
$1.36M
$1.29M
$1.32M
$1.61M
$1.15M
$1.44M
$1.14M
Research and development
$4.93M
$3.2M
$2.25M
$1.72M
$1.64M
$1.52M
$1.12M
$1.2M
Total operating expenses
$7.27M
$4.56M
$3.54M
$3.04M
$3.26M
$2.67M
$2.56M
$2.34M
Operating income
-$7.27M
-$4.56M
-$3.54M
-$3.04M
-$3.26M
-$2.67M
-$2.56M
-$2.34M
Interest expense
$0
-$2.75M
$0
$0
$0
$12K
$0
$0
Income before taxes
-$15.6M
-$7.31M
-$3.51M
-$3.02M
-$3.2M
-$2.66M
-$2.57M
-$2.34M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$14K
Net income
-$15.6M
-$7.31M
-$3.51M
-$3.02M
-$3.2M
-$2.66M
-$2.57M
-$2.36M
Net income attributable to common shareholders
-$15.6M
-$7.31M
-$3.51M
-$3.02M
-$3.2M
-$2.66M
-$2.57M
-$2.36M
EBITDA
-$7.26M
-$4.55M
-$3.53M
-$3.04M
-$3.25M
-$2.66M
-$2.56M
-$2.33M
Basic earnings per share
-$0.11
-$0.14
-$0.07
-$0.06
-$0.07
-$0.06
-$0.06
-$0.06
Diluted earnings per share
-$0.11
-$0.14
-$0.07
-$0.06
-$0.07
-$0.06
-$0.06
-$0.06
Recent news
Company coverage with links to the original publishers.
Entera Bio Ltd. (NASDAQ: ENTX), a clinical-stage biopharmaceutical company developing oral peptide therapies, announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company is advancing its lead candidate EB613 (oral PTH(1-34)) for osteoporosis treatment, which met primary and secondary endpoints in a Phase 2 study, with positive FDA feedback received on planned Phase 3 registrational studies.
Entera Bio received positive FDA feedback on its Phase 3 protocol for EB613, an oral osteoporosis tablet based on teriparatide. The FDA accepted the company's proposed single-study registrational strategy with approximately 750 postmenopausal women, using total hip bone mineral density at 12 months as the primary endpoint. Phase 3 is expected to initiate in late 2026 with topline results anticipated in H2 2028. The approval could represent the first oral anabolic osteoporosis treatment, addressing a market where injectable therapies have limited adoption despite high efficacy.
U.S. stock futures rose on Monday following Friday's sharp sell-off, with major indices recovering from correction territory. President Trump suggested the U.S. could seize Iran's oil infrastructure while characterizing Iran's new leaders as 'very reasonable.' Markets are pricing in a 96.4% likelihood of unchanged Fed rates in April. Key movers include Palantir Technologies, Rezolve AI, and Entera Bio, while analyst Mohamed El-Erian warns of 'stagflationary winds' and economic headwinds ahead.
U.S. stock futures rose on Monday following Friday's sharp sell-off, with major indices recovering from correction territory. President Trump's comments about Iran's new leaders being 'very reasonable' and potential oil agreements provided some market optimism. Key movers included Palantir (partnership expansion), Rezolve AI (raised revenue outlook), and Entera Bio (earnings miss). Analysts warn of 'stagflationary winds' and expect continued volatility ahead.
OPKO Health will report its financial results for Q4 and full year 2025 on February 26, 2026, followed by a conference call. The company has also expanded its partnership with Entera Bio to advance an oral long-acting PTH tablet for hypoparathyroidism treatment, marking the third successful program combining Entera's N-Tab platform with OPKO's protein chemistry capabilities.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.